Pankaj Bhargava

Pankaj Bhargava is interim Chief Medical Officer at Aktis Oncology, where he oversees all clinical development activities, in addition to serving as an Executive Partner at MPM Capital and a Clinical Assistant Professor at University of California, San Francisco. Pankaj has been involved in drug development for over two decades, during which time he oversaw several functional areas, filed multiple INDs and led global registration programs and drug approvals in US, EU and other regions. Most recently, Pankaj served as Vice President and Head of the Oncology Therapeutic Area at Gilead Sciences where he was responsible for driving oncology strategy and execution across programs. In this role, he led the expansion of the oncology pipeline through multiple partnerships and acquisitions. He previously served as Chief Medical Officer at Dicerna Pharmaceuticals and Tioma Therapeutics (now ARCH oncology), and held roles with increasing responsibilities at Sanofi Oncology and AVEO Pharmaceuticals. Pankaj earned his MD from the University of Delhi and completed his training in medical oncology and clinical pharmacology at Georgetown University, Lombardi Cancer Center and NIH.

Prior to his industry career, Pankaj was an Assistant Professor at Harvard Medical School and Dana-Farber Cancer Institute in Boston. In his spare time, Pankaj enjoys swimming, music and traveling the world with his family.